CDMO / CMOFounded 2007
Catalent, Inc.
Tampa, Florida, United States
A large-scale CDMO offering biologics manufacturing, softgel and oral dose formulation/manufacturing, cell and gene therapy production, and clinical trial packaging/supply services; became a major fill-finish partner for several COVID-19 vaccines.
- Segment
- CDMO / CMO
- Headquarters
- Tampa, Florida, United States
- Founded
- 2007
- Website
- www.catalent.com
Notable facts
- Formed as an independent company in 2007 when Cardinal Health divested its pharmaceutical technologies business, though its manufacturing lineage traces to R.P. Scherer Corporation's 1933 invention of the rotary-die softgel process.
- Provided drug-substance and fill-finish manufacturing capacity for COVID-19 vaccines from Pfizer-BioNTech, Johnson & Johnson, AstraZeneca, and Moderna.
- Acquired by Novo Holdings A/S in a deal that closed in December 2024, valued at roughly $16.5 billion, taking the company private after a decade on the NYSE (ticker CTLT).
- Operated approximately 53 manufacturing and development facilities with about 16,900 employees as of 2024.
Sourcing guides
Sources. This profile is compiled from public reference data, WebSearch-verified against source 1 · source 2. Data as of 2026-07-14. See methodology.
Sourcing a vendor in this segment today? We connect clinical operations, regulatory, and procurement teams with qualified cdmo / cmo vendors.
Request vendors